Two cases of bullous pemphigoid effectively treated with oral tofacitinib
Saved in:
| Published in: | JAAD Case Reports Vol. 32; pp. 77 - 80 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
01.02.2023
Elsevier |
| Subjects: | |
| ISSN: | 2352-5126, 2352-5126 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Author | Gallitano, Stephanie Bordone, Lindsey A. Youssef, Soundos |
|---|---|
| Author_xml | – sequence: 1 givenname: Soundos surname: Youssef fullname: Youssef, Soundos organization: Postdoctoral Research Fellow, Department of Dermatology, Columbia University Irving Medical Center, New York, New York – sequence: 2 givenname: Stephanie surname: Gallitano fullname: Gallitano, Stephanie organization: Assistant Professor, Department of Dermatology, Columbia University Irving Medical Center, New York, New York – sequence: 3 givenname: Lindsey A. surname: Bordone fullname: Bordone, Lindsey A. email: lab87@cumc.columbia.edu organization: Assistant Professor, Department of Dermatology, Columbia University Irving Medical Center, New York, New York |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36691585$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUk1vGyEUXFWpmo_mD_RQ7bEXu8CyLFRVpCrqh6VIPTQ9IxYeNlu8uIAd-d-XjdMoidT0BHq8mXmPmdPqaAwjVNUbjOYYYfZ-mA9GxzlBhJTCHBH-ojohTUtmLSbs6MH9uDpPaUAI4ZZ2TYdfVccNYwK3vD2pFtc3odYqQaqDrfut92Gb6g2sNyu3DM7UYC3o7Hbg93WOoDKY-sblVR2i8nUOVmmX3ej619VLq3yC87vzrPr55fP15bfZ1fevi8tPVzPdUsJnzBKEFTBFkbbCggBgYEAwaoihbYe4Rn3XEKwFRaJBtBGibIEt73uMOW3OqsWB1wQ1yE10axX3MignbwshLqWK2WkPkluhFbQNht7QRhuFgPe8U8Qw1JIOF66LA9dm26_BaBhz2eoR6eOX0a3kMuyk4AxhOg3z7o4ght9bSFmuXdLgvRqhfKQkHRNN13Zi0nr7UOte5K8XpYEcGnQMKUWw9y0YyclzOcjJczl5PtWK5wXEn4CKHSq7MM3r_PPQjwcoFLd2DqJM2sGowbhYLC_f6Z6HXzyBa19yoJX_BXtIQ9jGseRAYpmIRPLHlMcpjoQgRDljheDDvwn-p_4Hoz3vhA |
| CitedBy_id | crossref_primary_10_1177_12034754251351854 crossref_primary_10_3389_fimmu_2024_1464474 crossref_primary_10_3389_fimmu_2024_1343299 crossref_primary_10_1111_ajd_14389 crossref_primary_10_1186_s43556_025_00272_9 crossref_primary_10_3389_fimmu_2023_1220887 crossref_primary_10_1093_bjd_ljaf219 crossref_primary_10_1007_s00228_024_03621_9 crossref_primary_10_1016_j_jdcr_2024_12_017 crossref_primary_10_3389_fimmu_2025_1537428 crossref_primary_10_25259_IJDVL_300_2024 crossref_primary_10_3389_fimmu_2025_1563286 crossref_primary_10_1111_jdv_19475 crossref_primary_10_3389_fmed_2023_1196946 crossref_primary_10_1016_j_jaad_2023_02_015 |
| Cites_doi | 10.1002/ccr3.3325 10.1111/dth.15754 10.1007/s12026-017-8975-2 10.1016/j.jaad.2016.07.040 10.3389/fimmu.2017.01752 10.1159/000494613 10.1155/2017/6716419 10.1146/annurev-pathol-012615-044313 10.1111/bjd.14871 |
| ContentType | Journal Article |
| Copyright | 2022 American Academy of Dermatology, Inc. American Academy of Dermatology, Inc. 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc. This is an open access.. 2022 American Academy of Dermatology, Inc. |
| Copyright_xml | – notice: 2022 American Academy of Dermatology, Inc. – notice: American Academy of Dermatology, Inc. – notice: 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc. This is an open access.. 2022 American Academy of Dermatology, Inc. |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.jdcr.2022.10.028 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2352-5126 |
| EndPage | 80 |
| ExternalDocumentID | oai_doaj_org_article_8f9cae531ebd43cda0e8b87a2d605271 PMC9860144 36691585 10_1016_j_jdcr_2022_10_028 S2352512622004866 1_s2_0_S2352512622004866 |
| Genre | Case Reports |
| GroupedDBID | .1- .FO 0R~ 1P~ 4.4 457 53G 5VS AAEDT AAEDW AAIKJ AALRI AAXUO AAYWO ABMAC ACGFS ACVFH ADBBV ADCNI ADEZE ADVLN AEUPX AEXQZ AFJKZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BAWUL BCNDV EBS EJD FDB GROUPED_DOAJ HYE IPNFZ IXB KQ8 M41 M~E O9- OK1 RIG ROL RPM SSZ Z5R 0SF 6I. AACTN AAFTH AFCTW NCXOZ ABMYL AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5428-6f201ae6a40cf9fe9ee6ede964d2d45708c0b7321c94093043995121f8bb11843 |
| IEDL.DBID | DOA |
| ISSN | 2352-5126 |
| IngestDate | Fri Oct 03 12:30:53 EDT 2025 Thu Aug 21 18:38:51 EDT 2025 Thu Sep 04 17:28:07 EDT 2025 Thu Jan 02 22:52:10 EST 2025 Thu Nov 13 04:30:07 EST 2025 Tue Nov 18 21:31:38 EST 2025 Sat Mar 16 16:14:11 EDT 2024 Tue Feb 25 20:12:41 EST 2025 Tue Aug 26 16:31:59 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | bullous pemphigoid STAT JAK JAKi JAK inhibitor Janus kinase inhibitor BP tofacitinib treatment efficacy signal transducers and activators of transcription Janus kinase BP, bullous pemphigoid STAT, signal transducers and activators of transcription JAK, Janus kinase JAKi, Janus kinase inhibitor |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5428-6f201ae6a40cf9fe9ee6ede964d2d45708c0b7321c94093043995121f8bb11843 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| OpenAccessLink | https://doaj.org/article/8f9cae531ebd43cda0e8b87a2d605271 |
| PMID | 36691585 |
| PQID | 2769375791 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_8f9cae531ebd43cda0e8b87a2d605271 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9860144 proquest_miscellaneous_2769375791 pubmed_primary_36691585 crossref_primary_10_1016_j_jdcr_2022_10_028 crossref_citationtrail_10_1016_j_jdcr_2022_10_028 elsevier_sciencedirect_doi_10_1016_j_jdcr_2022_10_028 elsevier_clinicalkeyesjournals_1_s2_0_S2352512622004866 elsevier_clinicalkey_doi_10_1016_j_jdcr_2022_10_028 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-02-01 |
| PublicationDateYYYYMMDD | 2023-02-01 |
| PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAAD Case Reports |
| PublicationTitleAlternate | JAAD Case Rep |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Kridin (bib2) 2018; 66 Bissonnette, Papp, Poulin (bib9) 2016; 175 Hammers, Stanley (bib1) 2016; 11 Liu, Li, Xia (bib3) 2017; 8 Berbert Ferreira, Berbert Ferreira, Scheinberg (bib5) 2020; 8 (bib6) 2021 Feldman, Thaçi, Gooderham (bib8) 2016; 75 Almutairi, Nour, Hussain (bib4) 2019; 235 Xiao, Xiang, Li (bib7) 2022; 35 Juczynska, Wozniacka, Waszczykowska (bib10) 2017; 2017 Xiao (10.1016/j.jdcr.2022.10.028_bib7) 2022; 35 Juczynska (10.1016/j.jdcr.2022.10.028_bib10) 2017; 2017 Hammers (10.1016/j.jdcr.2022.10.028_bib1) 2016; 11 Liu (10.1016/j.jdcr.2022.10.028_bib3) 2017; 8 Kridin (10.1016/j.jdcr.2022.10.028_bib2) 2018; 66 Berbert Ferreira (10.1016/j.jdcr.2022.10.028_bib5) 2020; 8 Feldman (10.1016/j.jdcr.2022.10.028_bib8) 2016; 75 Almutairi (10.1016/j.jdcr.2022.10.028_bib4) 2019; 235 Bissonnette (10.1016/j.jdcr.2022.10.028_bib9) 2016; 175 36822352 - J Am Acad Dermatol. 2023 May;88(5):1004 |
| References_xml | – volume: 175 start-page: 902 year: 2016 end-page: 911 ident: bib9 article-title: Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial publication-title: Br J Dermatol – year: 2021 ident: bib6 article-title: FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. United States Food and Drug Administration – volume: 66 start-page: 6 year: 2018 end-page: 17 ident: bib2 article-title: Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations publication-title: Immunol Res – volume: 75 start-page: 1162 year: 2016 end-page: 1170.e3 ident: bib8 article-title: Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis publication-title: J Am Acad Dermatol – volume: 8 start-page: 3244 year: 2020 end-page: 3247 ident: bib5 article-title: Atopic dermatitis: tofacitinib, an option for refractory disease publication-title: Clin Case Rep – volume: 35 year: 2022 ident: bib7 article-title: Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib publication-title: Dermatol Ther – volume: 11 start-page: 175 year: 2016 end-page: 197 ident: bib1 article-title: Mechanisms of disease: pemphigus and bullous pemphigoid publication-title: Annu Rev Pathol – volume: 8 start-page: 1752 year: 2017 ident: bib3 article-title: BP180 is critical in the autoimmunity of bullous pemphigoid publication-title: Front Immunol – volume: 2017 start-page: 6716419 year: 2017 ident: bib10 article-title: Expression of the JAK/STAT signaling pathway in bullous pemphigoid and dermatitis Herpetiformis publication-title: Mediators Inflamm – volume: 235 start-page: 130 year: 2019 end-page: 136 ident: bib4 article-title: Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study publication-title: Dermatology – volume: 8 start-page: 3244 issue: 12 year: 2020 ident: 10.1016/j.jdcr.2022.10.028_bib5 article-title: Atopic dermatitis: tofacitinib, an option for refractory disease publication-title: Clin Case Rep doi: 10.1002/ccr3.3325 – volume: 35 issue: 10 year: 2022 ident: 10.1016/j.jdcr.2022.10.028_bib7 article-title: Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib publication-title: Dermatol Ther doi: 10.1111/dth.15754 – volume: 66 start-page: 6 issue: 1 year: 2018 ident: 10.1016/j.jdcr.2022.10.028_bib2 article-title: Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations publication-title: Immunol Res doi: 10.1007/s12026-017-8975-2 – volume: 75 start-page: 1162 issue: 6 year: 2016 ident: 10.1016/j.jdcr.2022.10.028_bib8 article-title: Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2016.07.040 – volume: 8 start-page: 1752 year: 2017 ident: 10.1016/j.jdcr.2022.10.028_bib3 article-title: BP180 is critical in the autoimmunity of bullous pemphigoid publication-title: Front Immunol doi: 10.3389/fimmu.2017.01752 – volume: 235 start-page: 130 issue: 2 year: 2019 ident: 10.1016/j.jdcr.2022.10.028_bib4 article-title: Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study publication-title: Dermatology doi: 10.1159/000494613 – volume: 2017 start-page: 6716419 year: 2017 ident: 10.1016/j.jdcr.2022.10.028_bib10 article-title: Expression of the JAK/STAT signaling pathway in bullous pemphigoid and dermatitis Herpetiformis publication-title: Mediators Inflamm doi: 10.1155/2017/6716419 – volume: 11 start-page: 175 year: 2016 ident: 10.1016/j.jdcr.2022.10.028_bib1 article-title: Mechanisms of disease: pemphigus and bullous pemphigoid publication-title: Annu Rev Pathol doi: 10.1146/annurev-pathol-012615-044313 – volume: 175 start-page: 902 issue: 5 year: 2016 ident: 10.1016/j.jdcr.2022.10.028_bib9 article-title: Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial publication-title: Br J Dermatol doi: 10.1111/bjd.14871 – reference: 36822352 - J Am Acad Dermatol. 2023 May;88(5):1004 |
| SSID | ssj0001547371 |
| Score | 2.3444831 |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 77 |
| SubjectTerms | bullous pemphigoid Case Report Dermatology JAK inhibitor Janus kinase inhibitor tofacitinib treatment efficacy |
| Title | Two cases of bullous pemphigoid effectively treated with oral tofacitinib |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2352512622004866 https://www.clinicalkey.es/playcontent/1-s2.0-S2352512622004866 https://dx.doi.org/10.1016/j.jdcr.2022.10.028 https://www.ncbi.nlm.nih.gov/pubmed/36691585 https://www.proquest.com/docview/2769375791 https://pubmed.ncbi.nlm.nih.gov/PMC9860144 https://doaj.org/article/8f9cae531ebd43cda0e8b87a2d605271 |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2352-5126 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001547371 issn: 2352-5126 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2352-5126 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001547371 issn: 2352-5126 databaseCode: M~E dateStart: 20150101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4s0WqIzEDQViJ_HjCKgVSLRCokh7s_yEVFVSNQsVF347M3Gy2gXUXrjsIRsn6_HnzDebmW8IeVH5xALzrJBAtgug1KGwdZCFAzbXuJonnUVcP8qjI7Vc6k8brb4wJyzLA2fDvVZJexsBKdGFuvLBllE5JS0PQMT5WD3OgfVsBFO5PriW1RhtcWAYBXg1MVXM5OSuk-BRDJTzV5jaha3YN7zSKN6_5Zz-Jp9_5lBuOKWDO-T2xCbpmzyLu-Ra7O6Rm4fT-_L75MPxRU89OKqB9ok6CDch0KdnEZaw_dq3geZ0Dnjinf6kY855DBT_mqVYuE9XfbK-XbVd6x6QLwf7x-_eF1PzhMI3EFIUIoFrt1HYuvRJp6hjFDFELerAQ93IUvnSyYozryHEq7BCFsgWZ0k5x7AJzEOy0_VdfExoqKXXQdcJO1XbEC2zCq4pUwxcpZIvCJuNZ_ykLI4NLk7NnEJ2YtDgBg2Ox8DgC_JyPeYs62pcevZbXJP1maiJPR4ApJgJKeYqpCxINa-omctO4UEJF2ovvbX816g4THt9MMwM3JTmMyINgcb5qGMoFqRZj5zoTKYpV97x-Qw3A3sdX-DYLgI8DMfGlbKRGubyKMNvbZJKCM0g9oPfuwXMLZttf9O130Y9ca0ExtW7_8PIT8gtmEqV89qfkp3V-ff4jNzwP1btcL5Hrsul2hu3Knwe_tr_DRKLQhw |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Two+cases+of+bullous+pemphigoid+effectively+treated+with+oral+tofacitinib&rft.jtitle=JAAD+Case+Reports&rft.au=Youssef%2C+Soundos&rft.au=Gallitano%2C+Stephanie&rft.au=Bordone%2C+Lindsey+A&rft.date=2023-02-01&rft.issn=2352-5126&rft.eissn=2352-5126&rft.volume=32&rft.spage=77&rft_id=info:doi/10.1016%2Fj.jdcr.2022.10.028&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F23525126%2Fcov200h.gif |